About Sientra (NASDAQ:SIEN)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SIEN
CUSIPN/A
Phone805-562-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio1.10%
Quick Ratio0.69%
Price-To-Earnings
Trailing P/E Ratio-4.55
Forward P/E Ratio-4.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.54 million
Price / Sales6.90
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book9.04
Profitability
EPS (Most Recent Fiscal Year)($2.82)
Net Income$-64,020,000.00
Net Margins-175.22%
Return on Equity-107.35%
Return on Assets-55.62%
Miscellaneous
Employees200
Outstanding Shares19,640,000
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra (NASDAQ:SIEN) announced its quarterly earnings data on Tuesday, March, 13th. The medical instruments supplier reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.21. The medical instruments supplier had revenue of $11.10 million for the quarter, compared to the consensus estimate of $11.90 million. Sientra had a negative net margin of 175.22% and a negative return on equity of 107.35%. The firm's revenue for the quarter was up 70.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.43) earnings per share. View Sientra's Earnings History.
What price target have analysts set for SIEN?
7 equities research analysts have issued twelve-month price objectives for Sientra's stock. Their predictions range from $12.00 to $18.00. On average, they expect Sientra's share price to reach $14.40 in the next twelve months. View Analyst Ratings for Sientra.
What are Wall Street analysts saying about Sientra stock?
Here are some recent quotes from research analysts about Sientra stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our BUY rating on Sientra following PMA-S approval of the company’s new Vesta manufacturing facility. The timing of approval comes in line with our recent expectations for H1/18 and brings a close to what has been a two-and-a- half-year process to secure regulatory approval for a new manufacturing partner and remediate inventory constraints on the company’s Opus silicone breast implants. As a reminder, earlier in the Q1/18 Sientra obtained approval for 3 of the 4 required PMA-S filings required for the new facility (additional details here), and the most recent approval now allows them to manufacture and sell inventory out of their new Vesta manufacturing facility. While the final FDA approval came later than expected, we remind investors that Sientra has been manufacturing breast implants since early in the Q4/17 in anticipation of securing FDA approval in H1/18." (4/19/2018)
- 2. According to Zacks Investment Research, "Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. " (3/17/2018)
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Achillion Pharmaceuticals (ACHN), ObsEva (OBSV), Zealand Pharma A/S (ZLDPF), Medical Facilities (DR), BioCryst Pharmaceuticals (BCRX), Innate Pharma (IPHYF), Community Health Systems (CYH), MediciNova (MNOV), Zealand Pharma (ZEAL), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Sinovac Biotech (SVA), PDL Biopharma (PDLI), Zeltia (PHMMF), Concert Pharmaceuticals (CNCE), Solid Biosciences (SLDB), Synergy Pharmaceuticals (SGYP) and Accuray (ARAY).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 71)
- Mr. Patrick F. Williams, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 45)
- Mr. Charles Huiner, Chief Operating Officer and Sr. VP of Corp. Devel. & Strategy (Age 47)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
- Mr. Jason O'Hearn, VP of Sales
Has Sientra been receiving favorable news coverage?
Media headlines about SIEN stock have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sientra earned a media sentiment score of 0.14 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 45.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $12.84.
How big of a company is Sientra?
Sientra has a market capitalization of $252.23 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Sientra employs 200 workers across the globe.
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sientra (NASDAQ:SIEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Sientra in the last 12 months. Their average twelve-month price target is $14.40, suggesting that the stock has a possible upside of 12.15%. The high price target for SIEN is $18.00 and the low price target for SIEN is $12.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.83 | 3.00 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.40 | $14.00 | $15.00 | $13.75 |
| Price Target Upside: | 12.15% upside | 36.72% upside | 45.21% upside | 13.68% downside |
Sientra (NASDAQ:SIEN) Consensus Price Target History
Sientra (NASDAQ:SIEN) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Sientra (NASDAQ:SIEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sientra (NASDAQ SIEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 77.38%
Sientra (NASDAQ SIEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/12/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 287,891 | $5.98 | $1,721,588.18 | |  |
| 10/9/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 666,609 | $7.18 | $4,786,252.62 | | |
| 10/6/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 193,000 | $8.71 | $1,681,030.00 | | |
| 10/1/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 101,898 | $10.24 | $1,043,435.52 | | |
| 9/28/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 150,908 | $10.58 | $1,596,606.64 | | |
| 10/29/2014 | Llp Abingworth | Major Shareholder | Buy | 495,000 | $15.00 | $7,425,000.00 | | |
(Data available from 1/1/2013 forward)
Sientra (NASDAQ SIEN) News Headlines
| Source: |
|
Sientra (NASDAQ:SIEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sientra (NASDAQ:SIEN) Income Statement, Balance Sheet and Cash Flow Statement
Sientra (NASDAQ SIEN) Stock Chart for Sunday, April, 22, 2018
Loading chart…
